<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520529</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190179</org_study_id>
    <nct_id>NCT04520529</nct_id>
  </id_info>
  <brief_title>Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas</brief_title>
  <acronym>LYMPHOTEQ</acronym>
  <official_title>Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of&#xD;
      cutaneous lymphomas is extremely variable from one subject to another. In the majority of&#xD;
      cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the&#xD;
      skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new&#xD;
      molecular prognostic factors will allow a better identification of patients at high risk of&#xD;
      aggressive evolution and the implementation of a personalized therapeutic strategy. The&#xD;
      identification of new therapeutic targets is necessary in order to develop new innovative&#xD;
      treatments for cutaneous lymphomas.The primary objective is to identify novel molecular&#xD;
      prognostic factors associated with 5-year overall survival in cutaneous lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2050</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2045</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cutaneous Lymphoma</condition>
  <arm_group>
    <arm_group_label>Patients with primary cutaneous lymphoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biologic Samples</intervention_name>
    <description>An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.&#xD;
an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.&#xD;
In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research.</description>
    <arm_group_label>Patients with primary cutaneous lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years old&#xD;
&#xD;
          -  Informed consent signed by the patient&#xD;
&#xD;
          -  Suspicion of primary cutaneous lymphoma or confirmed lymphoma according to&#xD;
             WHO/ISCL/EORTC criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Lack of affiliation to social security&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adèle DE MASSON</last_name>
    <phone>01 42 49 43 19</phone>
    <email>adele.demasson@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu RESCHE-RIGON</last_name>
    <phone>0142499742</phone>
    <phone_ext>0142499742</phone_ext>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

